From vaccine availability to effective deployment: Closing the arboviral vaccine access gap Authors: Kok Keng Tee, Dongkui Mu, Binghui Wang, Xueshan Xia Published: 2026 ABSTRACT ABSTRACTMosquito-borne viral diseases are expanding globally, yet programmatic access to dengue and chikungunya vaccines remains limited or uneven in many high-risk settings. Using country-level classifications of regulatory approval and national immunization program inclusion, we identify substantial gaps between vaccine availability and areas at greatest epidemiological risk. The central challenge extends beyond vaccine feasibility to a multilayered vaccine-access gap spanning initial availability, sustained deployment and alignment with transmission risk. Current vaccine strategies remain reactive and insufficiently adapted to epidemiological patterns and health-system demands. Closing this gap will require preparedness-oriented frameworks that support timely introduction, durable coverage, and risk-adaptive deployment. Arboviral risk outpacing vaccine access Mosquito-borne viral diseases are among the fastest-growing infectious threats worldwide. Dengue, chikungunya, Japanese encephalitis, Zika, and other arboviral infections are being reshaped by climate change, urbanization, land-use change, and human mobility, enabling transmission in settings where these diseases were previously rare or absent.1,2 Yet while epidemiological risk continues to intensify, access to preventive tools has not kept pace. The resulting gap between arboviral risk and access to licensed vaccines reflects a system-level challenge that lies not in scientific feasibility, but in how vaccine systems are designed and implemented.3,4 Licensed human vaccines are already available for several mosquito-borne viral diseases of global and regional importance, including dengue, Japanese encephalitis, yellow fever, and, more recently, chikungunya. However, their use remains uneven across regions and pathogens. Vaccines against yellow fever and Japanese encephalitis have long been incorporated into routine immunization or large-scale public health programs in endemic settings, whereas dengue and chikungunya vaccines have seen more limited or recent uptake.5,6 Although dengue, chikungunya, yellow fever, and Japanese encephalitis differ substantially in their epidemiology, regulatory maturity, and deployment requirements, they share broader challenges related to financing, procurement, delivery, and long-term program sustainability. The challenge is therefore not to apply a single vaccination model across arboviruses, but to develop deployment strategies adapted to pathogen-specific epidemiology while supported by more resilient vaccine access systems. Dengue and chikungunya best illustrate the current access challenge (Supplementary Table 1). Dengvaxia, although licensed in several countries, is restricted to individuals with documented prior dengue infection because of safety concerns, whereas the newer tetravalent vaccine Qdenga has received regulatory approval in multiple regions but remains only partially adopted and not yet embedded in national programs.5,6 Brazil provides a notable exception, having introduced the tetravalent dengue vaccine into its national immunization program, although implementation remains phased and geographically targeted, reflecting supply constraints and evolving policy considerations. Chikungunya vaccines have only recently entered the market, with the live-attenuated Ixchiq and recombinant virus-like particle vaccine Vimkunya representing important scientific advances; however, use remains largely confined to early-adopter markets and travel-related contexts rather than to endemic population-level deployment. This pattern raises practical concerns, as vaccination is often prioritized for travelers from lower-risk settings while access to vaccination remains limited in many endemic populations. By contrast, Japanese encephalitis and yellow fever vaccines have a much longer programmatic history, with routine use in several endemic countries despite persistent subnational and cross-country gaps in coverage. For several arboviruses – particularly dengue and chikungunya – the challenge is therefore no longer vaccine discovery alone, but translating licensure into sustained and appropriately targeted protection. Importantly, evolving evidence on long-term effectiveness, population-specific performance, and vaccine safety will continue to shape regulatory recommendations and public-health adoption of newer arboviral vaccines. Crucially, this is not only a problem of initial access. Even where vaccines exist, delivery can falter under political, financial, and programmatic constraints. The Dengvaxia episode in the Philippines showed how safety concerns can erode confidence and disrupt broader immunization efforts, while the longer histories of Japanese encephalitis and yellow fever vaccination show that durable impact depends on sustained program capacity.7–9 The arboviral vaccine access paradox These program-level challenges are mirrored at the global level: when considered alongside global patterns of vaccine availability and use, the geographic overlap between arboviral transmission risk, vector suitability, and access to licensed vaccines (Figure 1 and Supplementary Figure 1) reveals a striking disconnect between rising risk and limited vaccine access. In the analyses presented here, vaccine access was evaluated as a multidimensional construct encompassing regulatory approval, market availability, program implementation, program scope, eligibility restrictions, and vaccine coverage, recognizing that these components represent distinct stages of vaccine deployment. The ecological conditions required for transmission are already widespread: Aedes aegypti and Aedes albopictus, the principal mosquito vectors of dengue, chikungunya, and urban yellow fever, are present in approximately 68% of countries worldwide. Yet access to licensed vaccines remains limited in many of the areas most affected by disease. Among countries with endemic or sustained dengue transmission, approximately 78% lack a licensed dengue vaccine, while more than 95% of countries experiencing sporadic or introduced dengue outbreaks similarly have no vaccine access. A comparable pattern is evident for chikungunya – approximately 95% of countries with endemic, autochthonous, and sporadic transmission currently lack licensed vaccines (Figure 1). Figure 1.Global overlap between arboviral transmission risk and access to licensed vaccines for dengue (A) and chikungunya (B).A map of dengue transmission risk shows regions with varying levels of Aedes vector presence and transmission types. Categories include no vectors, limited presence, imported cases, sporadic outbreaks, autochthonous transmission and endemic transmission. Areas with vaccine availability are marked with hatching. High transmission risk is seen in parts of South America, Africa and South Asia. A map of chikungunya transmission risk displays similar categories, with endemic transmission in parts of South America, Africa and South Asia. Both maps highlight the disconnect between transmission risk and vaccine access globally.Two world maps show dengue and chikungunya transmission risk and vaccine availability.Countries are classified according to the presence of Aedes mosquito vectors (Aedes aegypti or Aedes albopictus), reported patterns of dengue virus (DENV) and chikungunya virus (CHIKV) transmission, and access to licensed vaccines. The map highlights a mismatch between transmission risk and access to licensed vaccines. Estimates of countries lacking access were derived by integrating transmission classification with vaccine access status (see Supplementary Methods).Vector distribution data were compiled from global occurrence datasets and surveillance maps, including published global occurrence datasets, ECDC invasive mosquito monitoring datasets, and CDC vector distribution maps. Aedesvector presence indicates ecological suitability for transmission but does not necessarily imply endemic virus circulation. Documented local transmission does not necessarily indicate sustained endemic circulation. Virus circulation classifications were derived from global surveillance reports, including WHO Disease Outbreak News, ECDC surveillance updates, CDC travel health data, PAHO arbovirus surveillance, and national public-health sources. Access to licensed vaccines was evaluated using a multidimensional framework comprising regulatory approval, market availability, program implementation, program scope, eligibility restrictions, and vaccine coverage where available. For presentation of the maps, countries were classified using the composite vaccine-access categories defined in Supplementary Methods and Supplementary Dataset S1. Global overlap between arboviral transmission risk and access to licensed vaccines for dengue (A) and chikungunya (B). These patterns highlight a persistent paradox: regions experiencing recurrent outbreaks or sustained transmission often coincide with areas where access to licensed vaccines is constrained or delayed, while early access to licensed vaccines has frequently emerged in settings with comparatively lower population-level risk. Such patterns indicate a disconnect between arboviral transmission risk and vaccine deployment across jurisdictions. Several structural factors – including fragmented financing, regulatory heterogeneity, procurement constraints, manufacturing capacity, and immunization-system readiness – have been proposed in previous studies as contributors to delayed vaccine introduction. However, these determinants were not evaluated directly in the present analysis and should therefore be regarded as potential explanations rather than conclusions derived from our dataset. Recent WHO analyses similarly emphasize that vaccine introduction for emerging arboviruses often lags behind epidemiological risk, particularly in low- and middle-income settings where regulatory and financing pathways remain constrained.5 The gap between vaccine innovation and protection is therefore structural rather than pathogen-specific, arising from fragmented financing, uneven regulatory pathways, weak procurement mechanisms, and limited integration of arboviral vaccines into long-term immunization systems. This inequity is especially concerning because arboviral burden is still expanding.10 Dengue reached record global levels in 2023–2024, and chikungunya resurged across the Americas, Asia, the Indian Ocean region, and parts of Europe in 2025.11,12 As these diseases expand geographically, delayed vaccine deployment risks reproducing, rather than reducing, global health inequity. Barriers to deployment of arboviral vaccines The present analysis does not identify the reasons underlying vaccine introduction or non-introduction in individual countries. The factors discussed below are therefore drawn from the broader literature to provide context for the observed jurisdiction-level patterns rather than representing determinants evaluated directly in this study. A central constraint in vaccine deployment is market fragmentation and demand uncertainty, with arboviral vaccines still treated as outbreak-contingent rather than programmatic tools, resulting in irregular procurement and weak demand signals. Economic analyses have shown that such uncertainty undermines incentives for manufacturers to scale production, sustains high per-dose costs, and discourages long-term investment in production and distribution.13 Even for dengue, where disease burden is well documented, national adoption has been cautious and uneven following early post-licensure controversies and evolving eligibility guidance.6 Demand and deployment are also not uniform across pathogens: dengue has a more mature policy landscape than chikungunya, whereas yellow fever and Japanese encephalitis have long-established program pathways. Regulatory asymmetry further compounds these challenges. Approval in one jurisdiction rarely translates into rapid availability elsewhere, as arboviral vaccines often undergo full domestic regulatory review despite support from large multinational trials. In contrast to respiratory pathogens with pandemic potential such as influenza and COVID-19, few regions have established accelerated or conditional regulatory pathways for vector-borne diseases with recurrent outbreak risk.3 Addressing this gap will require leadership from global and regional agencies, including WHO, the Coalition for Epidemic Preparedness Innovations (CEPI), and regional regulatory networks, to develop harmonized regulatory pathways and support accelerated evaluation for arboviral vaccines. However, global policy recommendations do not automatically result in national implementation, as decisions remain shaped by political priorities, financing constraints, and delivery capacity. Safety controversies have further reinforced caution. The dengue vaccine experience showed how context-specific safety concerns can reshape national policy, depress confidence, and slow adoption of newer arboviral vaccines.4,14 Even where policy and regulatory pathways exist, operational and programmatic barriers can still limit vaccine delivery. Many arboviral vaccines target adolescents or adults rather than infants, or require serostatus-based eligibility, complicating integration into existing immunization platforms. Multi-dose schedules, cold-chain requirements, and uncertainty over financing mechanisms further complicate implementation, as arboviral vaccines often fall outside established funding structures for routine childhood immunization or emergency response, creating ambiguity around procurement, co-financing, and long-term program sustainability. In many settings, limited availability of high-resolution burden, seroprevalence, and cost-effectiveness data further constrains decision-making, delaying vaccine introduction despite recognized transmission risk.3 Importantly, non-introduction should not automatically be interpreted as evidence of inadequate policy or inequitable access. In some settings, decisions not to introduce a vaccine may appropriately reflect limited or geographically restricted disease burden, evolving evidence on vaccine effectiveness or safety, age- or serostatus-specific eligibility, unfavorable cost-effectiveness assessments, constrained global supply, competing public-health priorities, or an ongoing national policy review. These country-specific considerations were beyond the scope of the present analysis, which was designed to describe jurisdiction-level patterns of vaccine deployment rather than evaluate national decision-making processes. Toward preparedness-oriented vaccination strategies Several epidemic-prone infectious diseases have benefited from coordinated access mechanisms, including stockpiles, pooled procurement, advance purchase commitments, and pre-agreed deployment frameworks that support more rapid access during public-health emergencies.15 The COVID-19 pandemic further demonstrated that emergency regulatory pathways and pooled procurement systems can be mobilized at scale when political and financial incentives align. For most mosquito-borne viruses, however, comparable access architecture is lacking. Vaccination therefore remains predominantly post-outbreak, considered only after substantial transmission has occurred. This approach limits the potential of vaccines to dampen outbreak amplification, reduce cumulative morbidity and long-term complications, or alleviate pressure on outpatient and hospital services during peak transmission seasons. Addressing the arboviral vaccine gap does not require immediate mass immunization or universal coverage, but a structural shift from post-outbreak response to risk-informed preparedness-oriented vaccination strategies. For newly licensed vaccines such as those against chikungunya, this approach may initially involve targeted deployment in high-risk populations or outbreak-prone settings rather than broad population-wide vaccination. This shift begins with defining deployability in advance through pre-outbreak policy frameworks that specify target populations, risk-based triggers for deployment, prioritization under constrained supply, pharmacovigilance strategies, financing arrangements, and mechanisms for ongoing evaluation. Depending on pathogen characteristics, vaccine maturity, and local epidemiology, deployment may range from incorporation into routine immunization programs to targeted vaccination in high-risk populations or during periods of elevated transmission. Preparedness must also include sustained delivery. The histories of Japanese encephalitis and yellow fever vaccination show that durable impact depends not only on licensure, but also on sustained financing, program incorporation, and surveillance capable of identifying immunity gaps.7–9 For dengue and chikungunya, preparedness must therefore extend beyond initial access to delivery platforms able to maintain coverage across multiple cohorts and transmission seasons. Beyond sustaining coverage over time, a further challenge lies in aligning vaccination strategies with the transmission patterns of arboviral diseases. The relative success of Japanese encephalitis and yellow fever vaccination should not be interpreted as evidence that the same programmatic model can be directly transferred to dengue or chikungunya. Japanese encephalitis has largely been addressed through childhood-focused immunization in geographically recognizable endemic settings, while yellow fever benefits from a highly effective vaccine and clearer preventive targeting. By contrast, dengue and chikungunya are more strongly shaped by urban transmission dynamics, population mobility, and subnational variability, making them less amenable to uniform national strategies. Unlike many vaccine-preventable infections with relatively stable epidemiology, arboviral transmission is often influenced by climatic and ecological variability, with risk varying substantially across regions and over time, and likely evolving further as climate change expands the geographic range of Aedes vectors. Vaccination strategies are therefore often misaligned when designed as national programs that do not reflect local variation in risk. Dengue transmission, for example, can fluctuate markedly between years and across urban settings, while Japanese encephalitis risk is closely linked to ecological and agricultural conditions that vary geographically.2 Without approaches that incorporate real-time surveillance, climate-informed risk modeling, and subnational targeting, vaccination programs may be deployed too late, too broadly, or in populations with relatively low risk. Translating such approaches into action, however, remains challenging, particularly in resource-constrained settings. Early warning signals, such as sustained increases in reported cases, elevated vector indices, or climate conditions favoring transmission, require clear decision thresholds, coordinated governance, and timely deployment capacity, which are often limited in low-income settings. Preparedness for dengue and chikungunya will therefore require more adaptive models that link risk assessment to practical deployment decisions. In practice, operationalizing such a preparedness framework will require linking dynamic risk assessment to delivery systems while recognizing that implementation pathways should differ according to vaccine maturity, indications, and epidemiology. Long-established routine vaccines, such as those against Japanese encephalitis and yellow fever, should prioritize sustaining program performance, maintaining high coverage, and addressing residual geographic and population immunity gaps. By contrast, newly licensed vaccines, including those against chikungunya, may initially require phased introduction, robust post-licensure safety monitoring, flexible procurement mechanisms, and targeted deployment in high-risk populations or outbreak-prone settings. Dengue vaccination strategies should continue to reflect product-specific recommendations, local transmission intensity, and eligibility criteria, including age- or serostatus-based considerations where applicable. Across all arboviral vaccines, vaccination programs should be designed around subnational epidemiology and seasonal risk, while anchored in delivery platforms capable of sustaining coverage across multiple cohorts, including school-based and adult immunization where appropriate. Predictable financing, procurement, and, where appropriate, stockpiling will be needed to avoid recurrent interruptions. Unlike acute outbreak-prone infections managed through short-term emergency stockpiles, many arboviruses have sustained and geographically variable transmission, limiting the effectiveness of centrally managed global stockpiles alone. Hybrid approaches combining regional stockpiling with risk-informed procurement and preparedness planning may therefore be more appropriate. Lessons from COVID-19 pooled procurement mechanisms, including COVID-19 Vaccines Global Access (COVAX), further highlight the need for predictable financing and pre-agreed allocation frameworks. Robust post-licensure safety monitoring and transparent risk communication remain essential for maintaining public confidence. Preparedness therefore requires an iterative pathway that links surveillance and risk assessment to predefined deployment decisions, secures financing and procurement mechanisms before outbreaks occur, supports implementation through appropriate delivery platforms, and incorporates post-licensure safety monitoring and continuous evaluation to refine subsequent deployment. Together, these elements provide a structured preparedness framework that enables vaccination strategies to adapt to differing pathogen characteristics, vaccine products, and evolving epidemiological conditions. Conclusion Scientific progress has delivered vaccines for several major arboviral diseases, but the path from licensure to effective public-health deployment remains influenced by persistent challenges in access architecture, weak program continuity, and inadequate alignment between vaccination strategies and transmission risk. Closing the arboviral vaccine gap therefore requires more than introducing new products: it requires preparedness-oriented systems that can deliver vaccines equitably, maintain coverage, reduce clinical burden, and adapt deployment to evolving epidemiology. Unless such systems are built, arboviral vaccination will remain reactive and incomplete even as the burden of mosquito-borne disease continues to expand globally. Supplementary Material Supplementary Methods Appendix.docx